Early detection of diseases in low dose chest CT beyond lung cancer: Why and how?

Lung cancer screening has popularized the use of low-dose chest CT. These scans offer potential for detecting other degenerative diseases with prognostic implications in addition to lung cancer. 

If, when, and how to evaluate early CT signs of diseases beyond lung nodules and lung cancer are topics of ongoing debate. With burgeoning imaging biomarkers, radiologists are confronted with an increasing workload, while there are limited guidelines on management of ‘incidental’ findings on low dose chest CT. In this talk the current evidence for the evaluation of early signs of degenerative diseases on these scans is discussed, the role of automated AI software for chest CT imaging biomarkers is elucidated and recommendations for evaluating and reporting incidental findings are highlighted.